FUE hair transplant risks: a mini-systematic review and evidence round-up (2023–2025)

How the evidence was selected: Criteria for the latest PubMed evidence

A targeted search strategy was applied to PubMed to identify recent publications addressing complications, donor-site healing and peri-operative risk reduction in hair transplantation with direct relevance to FUE. Priority was given to studies explicitly referencing FUE, donor-area healing and complication reporting. The final evidence set includes a 2025 systematic review and meta-analysis of complications, a 2025 scoping review of complication breadth, an FUE donor-site healing systematic review, a 2025 systematic review in a high-risk alopecia subgroup and a 2023 international expert consensus statement on peri-operative care.

Donor-site risks in FUE: What patients most commonly experience

Since FUE relies on extracting thousands of follicular units from the donor area, this region absorbs most of the surgical micro-trauma, so the most common, earliest post-operative effects and the most clinically relevant short-term risks typically originate in the donor zone.

Pain, swelling and edema

Across pooled complication reporting, donor-site pain/discomfort and swelling/edema are the most consistent early adverse effects after hair transplantation and are therefore central to FUE risk counseling.

Folliculitis and donor-area inflammation

Donor-area inflammation and folliculitis are clinically important because they can worsen discomfort, prolong recovery and contribute to visible donor-area morbidity. Evidence focused specifically on donor-site care in FUE highlights that early post-operative wound care is associated with decreased folliculitis incidence, reinforcing donor aftercare as a genuine risk modifier rather than a cosmetic “extra.”

Recipient-site risks in FUE: Scarring and healing variability

Recipient-site scarring emerges as a key reported complication in pooled complication evidence. While the degree of scarring varies and is technique and healing-dependent, its repeated appearance across complication synthesis supports its inclusion as a standard risk disclosure for FUE recipients, particularly in patients prone to hypertrophic response or those seeking high-density packing.

The broader scoping review underscores that recipient-site complications can be heterogeneous in definition and reporting across the literature, which is itself a practical risk: inconsistent reporting can lead patients to underestimate the likelihood of minor but meaningful healing-related events.

Rare but high-impact complication signal: Donor-site AVF associated with punch-based FUE

A high-salience finding from the 2025 complications meta-analysis is the presence of reported donor-site arteriovenous fistulas (AVFs) in the literature, which were “often associated” with use of punch graft technique for FUE. This is a rare event, but it is clinically meaningful because it reflects potential iatrogenic vascular injury risk linked to extraction mechanics and depth control.

Clinical implication: Even when absolute incidence is low, the consequence profile justifies heightened technique discipline (depth/angle control) and explicit counseling that “rare” does not mean “impossible.”

Donor-site healing: Evidence-based interventions that may reduce morbidity

A 2025 systematic review focused on donor-site healing in FUE evaluated intra and post-operative interventions and linked them to clinically relevant endpoints (edema, folliculitis, healing dynamics). Key signals include:

• Intra-operative corticosteroid use may reduce post-operative edema by modulating local inflammation and vascular permeability.
• Early post-operative wound care is associated with reduced folliculitis incidence.
• PRP and hair follicle-derived microtissue (HFMT) show potential for wound-healing enhancement, but evidence is limited by heterogeneity and lack of standardized endpoints.

This donor-area synthesis supports positioning donor management as a primary pillar of FUE risk reduction, not just recipient artistry.

Special-risk population: FUE in primary cicatricial alopecia (PCA)

In patients with inactive primary cicatricial alopecia (PCA) undergoing hair transplantation (FUE or FUT), a 2025 systematic review reported that graft survival tends to peak at ~1 year and diminish over time and documented disease reactivation in a subset of patients. Although this literature includes both FUE and FUT, it is directly relevant to FUE risk assessment because PCA introduces a distinct complication domain: reactivation of an inflammatory scarring process, which can compromise outcomes beyond typical surgical healing risks.

Practical implication: PCA candidates require stricter selection and longer-term counseling on durability and reactivation risk than standard androgenetic alopecia candidates.

Pre and post-operative risk reduction: Consensus-based best practices

An international expert consensus statement (Delphi-based) provides practical peri-operative recommendations relevant to complication minimization, emphasizing:

• Appropriate candidate selection and ensuring adequate medical therapy for alopecia before transplant.
• Assessment of comorbidities during surgical planning.
• Withdrawal of certain medications associated with increased bleeding risk prior to surgery.
• Clear post-operative guidance and close follow-up during the first year after transplant.

These recommendations align with the complication literature by targeting modifiable drivers of bleeding/inflammation and improving early detection of post-op issues.

Key predictors of FUE risk identified across the evidence

Across the included PubMed evidence, the most consistent risk themes for FUE are:

• Donor-site morbidity (pain/discomfort, swelling/edema) as the most frequent early burden.
• Donor-area inflammatory complications (folliculitis) that are modifiable via early wound care.
• Recipient-site scarring as a repeatedly reported complication signal.
• Rare vascular injury events (AVF) reported and often linked to punch-based FUE technique.
• Indication-dependent risk (PCA reactivation and declining long-term survival in scarring alopecia).
• Peri-operative planning quality (candidate selection, bleeding-risk medication management, follow-up).

Clinical implications: What the evidence means for practice

• Most FUE risks are concentrated in donor-site symptoms and healing-related morbidity, which should be treated as core counseling points.
• Technique and extraction mechanics matter, given rare but serious vascular complication reports associated with punch-based FUE.
• Donor aftercare is a true risk modifier, with evidence linking early care to lower folliculitis incidence.
• In scarring alopecia, risk extends beyond surgical healing to reactivation and long-term durability limitations, requiring stricter patient selection and expectations management.
• Consensus guidance supports reducing avoidable complications through bleeding-risk medication review, individualized peri-operative planning and structured follow-up. 

Bibliography: The five latest PubMed-indexed articles considered

• Khatib M. Complications Following Hair Transplantation: A Systematic Literature Review and Meta-Analysis. Aesthetic Plast Surg. 2025. PMID: 40913181.
• Liu R.H. A Scoping Review on Complications in Modern Hair Transplantation: More than Just Splitting Hairs. Aesthetic Plast Surg. 2025. PMID: 39179656.
• Yii V. A Systematic Review of Follicular Unit Graft Survival Rates After Hair Transplantation in Primary Cicatricial Alopecia. Dermatol Surg. 2025. PMID: 40439233.
• Pérez N.A. Donor Site Healing in Follicular Unit Extraction Hair Transplantation: Current Evidence, Cellular Mechanisms and Future Research Directions. Cell Mol Biol. 2025. PMID: 40920315.
• Vañó-Galván S. An International Expert Consensus Statement Focusing on Pre- and Post-Hair Transplantation Care. J Dermatolog Treat. 2023. PMID: 37477225.